Top

Published in:

01-06-2021 | Multiple Sclerosis | Letter to the Editors

Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis

Authors: Vittorio Mantero, Damiano Baroncini, Roberto Balgera, Clara Guaschino, Paola Basilico, Pietro Annovazzi, Mauro Zaffaroni, Andrea Salmaggi, Christian Cordano

Published in: Journal of Neurology | Issue 6/2021

Excerpt

Dear Editor, …

Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R (2020) COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol 3:1–7. https://doi.org/10.1007/s00415-020-09944-8CrossRef

Möhn N, Saker F, Bonda V et al (2020) Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse. J Neurol 28:1–3. https://doi.org/10.1007/s00415-020-09921-1CrossRef

Luna G, Alping P, Burman J et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77:184–191. https://doi.org/10.1001/jamaneurol.2019.3365CrossRefPubMed

Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Marrie RA, Tremlett H (2017) Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler 23(11):1506–1516CrossRefPubMed

Steelman AJ (2015) Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol 6:520. https://doi.org/10.3389/fimmu.2015.00520CrossRefPubMedPubMedCentral

Sormani MP (2020) An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. https://doi.org/10.1016/S1474-4422(20)30147-2CrossRefPubMedPubMedCentral

Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2020.102180CrossRefPubMedPubMedCentral

Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH (2020) Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord 42:102180. https://doi.org/10.1016/j.msard.2020.102180CrossRefPubMedPubMedCentral

Novi G, Mikulska M, Briano F et al (2020) COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 42:102120. https://doi.org/10.1016/j.msard.2020.102120CrossRefPubMedPubMedCentral

10.

Carandini T, Pietroboni AM, Sacchi L et al (2020) Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: a mild uncomplicated infection despite intense immunosuppression. Mult Scler. https://doi.org/10.1177/1352458520926459CrossRefPubMed

11.

Aguirre C, Meca-Lallana V, Barrios-Blandino A, Del Río B, Vivancos J (2020) Covid-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role? Mult Scler Relat Disord 44:102250. https://doi.org/10.1016/j.msard.2020.102250CrossRefPubMedPubMedCentral

12.

Mantero V, Abate L, Basilico P, Balgera R, Salmaggi A, Nourbakhsh B, Cordano C (2020) COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. J Neurol 25:1–3. https://doi.org/10.1007/s00415-020-10015-1CrossRef

13.

Cai S, Sun W, Li M, Dong L (2020) A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. Clin Rheumatol 39:2797–2802. https://doi.org/10.1007/s10067-020-05234-wCrossRefPubMedPubMedCentral

14.

Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology 94:949–952. https://doi.org/10.1212/WNL.0000000000009507CrossRefPubMed

Title: Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis
Authors: Vittorio Mantero
Damiano Baroncini
Roberto Balgera
Clara Guaschino
Paola Basilico
Pietro Annovazzi
Mauro Zaffaroni
Andrea Salmaggi
Christian Cordano
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Sclerosis
Leflunomide
COVID-19
Teriflunomide
Published in: Journal of Neurology / Issue 6/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10196-9

At a glance: The STEP trials

Springer Medicine

Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2021

Ludwik Maurycy Hirschfeld (1814–1876)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy

Why do SARS-CoV-2 NSPs rush to the ER?

Feasibility study of assessing the Preclinical Alzheimer Cognitive Composite (PACC) score via videoconferencing

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis

Dystonia in Angelman syndrome: a common, unrecognized clinical finding